Magic Mushroom Compound Shows Promise Against Cocaine Addiction

Why It Matters

The results suggest a potentially breakthrough, non‑opioid therapy for cocaine use disorder, a condition with no approved pharmacologic treatment and rising prevalence. Success in a low‑income, predominantly Black sample highlights both clinical promise and equity implications.

Key Takeaways

• Psilocybin group achieved 30% complete abstinence at 180 days.
• Placebo group showed zero abstinence; psilocybin users cut use to 1.5 times/month.
• Study sample: >80% Black, 65% earned under $20,000 annually.
• Participants received CBT plus five integration psychotherapy sessions.
• Researchers urge larger, multisite trials to confirm findings.

Pulse Analysis

Cocaine addiction remains a public‑health crisis, with annual U.S. treatment costs soaring into the billions and no FDA‑approved medication to curb use. While traditional approaches rely on behavioral counseling and off‑label drugs with limited success, the resurgence of psychedelic research offers a novel pharmacologic avenue. Psilocybin, the active compound in magic mushrooms, has already shown efficacy for depression, PTSD, and smoking cessation, prompting investigators to explore its impact on stimulant disorders.

The University of Alabama at Birmingham trial distinguished itself by enrolling a demographically representative cohort—over four‑fifths Black and a majority living on less than $20,000 a year—countering the typical college‑educated, higher‑income bias of earlier psychedelic studies. Participants received a single high‑dose psilocybin session, intensive preparatory counseling, and post‑session integration therapy, mirroring best‑practice protocols for psychedelic‑assisted treatment. At six months, six of the twenty psilocybin recipients reported zero cocaine use confirmed by urine tests, while the placebo group showed no abstinence. Even among those who continued using, frequency dropped from an average of twelve uses per month to just 1.5, indicating a substantial behavioral shift.

If replicated, these findings could reshape the therapeutic landscape for stimulant use disorders, offering a rapid‑acting, low‑side‑effect alternative to current off‑label regimens. The study also underscores the importance of inclusive research designs that reflect the communities most burdened by addiction. Industry stakeholders are now eyeing partnerships to fund larger, multisite trials, which could accelerate regulatory pathways and bring a groundbreaking treatment to market, potentially reducing the societal and economic toll of cocaine addiction.